تقييم نشاط انزيم الارجنيز وبعض المتغيرات الكيموحيوية في امصال المرضى المصابين بتضخم الأطراف

Bandeira F, Lemos ALP, de Lima Andrade SR. Acromegaly. In: Bandeira F, Gharib H, Griz L, Faria M, editors. Endocrinology and Diabetes: A Problem Oriented Approach. Cham: Springer International Publishing; 2022:p. 55-60. https://doi.org/10.1007/978-3-030-90684-9_6

Langlois F, Suarez GM, Fleseriu M. Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly. F1000Res. 2020; 9. https://doi.org/10.12688/f1000research.22683.1

Badiu C, Witek P. Insights Into Acromegaly Complications. Front Endocrinol. 2022; 13: 905145. https://doi.org/10.3389/fendo.2022.905145

Coronel-Restrepo N, Syro LV, Rotondo F, Kovacs K. Anatomy of the Pituitary Gland. Pituitary Adenomas: The European Neuroendocrine Association’s Young Researcher Committee Overview: Springer; 2022: 1-19. https://doi.org/10.1007/978-3-030-90475-3_1

Gierach M, Junik R. Aberrations in carbohydrate metabolism in patients with diagnosed acromegaly bservational study. Endokrynol Pol. 2022; 73(4): 743-744. https://doi.org/10.5603/ep.a2022.0034

Sibeoni J, Manolios E, Verneuil L, Chanson P, Revah-Levy A. Patients’ perspectives on acromegaly diagnostic delay: a qualitative study. Eur J Endocrinol. 2019; 180(6): 339-52.https://doi.org/10.1530/EJE-18-0925

Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications Signal Transduct. Target Ther. 2019; 4(1): 3. https://doi.org/10.1038/s41392-019-0036-y

Chesnokova V. The Multiple Faces of the GH/IGF Axis. Cells. 2022; 11(2): 217. https://doi.org/10.3390/cells11020217

Moriyama S. Handbook of Hormones: Comparative Endocrinology for Basic and Clinical. Second Edition. England: Oxford: Elsevier, Academic Press; 2021. Subchapter 24A, Growth hormone; p. 199–201. https://doi.org/10.1016/B978-0-12-820649-2.00053-X

Lu M, Flanagan JU, Langley RJ, Hay MP, Perry JK. Targeting growth hormone function: strategies and therapeutic applications. Signal Transduct Target Ther. 2019; 4(1): 3. https://doi.org/10.1038/s41392-019-0036-y

Wondisford FE. Essentials of Endocrinology and Metabolism: A Practical Guide for Medical Students: Springer Nature; 2020: p. 229–40. https://doi.org/10.1007/978-3-030-39572-8_26

Kim S-H, Park M-J. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab. 2017; 22(3): 145 .https://doi.org/10.6065/apem.2017.22.3.145

Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020; 9(9): 1970. https://doi.org/10.3390/cells9091970

AsghariHanjani N, Vafa M. The role of IGF-1 in obesity, cardiovascular disease, and cancer. Med J Islam Repub Iran. 2019; 33(1): 1–4.

Kumari N, Bansal S. Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment. Cancer Chemother Pharmacol. 2021; 88: 565-94. https://doi.org/10.1007/s00280-021-04335-w

16. Ren Y, Li Z, Li W, Fan X, Han F, Huang Y, et al. Arginase: Biological and Therapeutic Implications in Diabetes Mellitus and Its Complications. Oxid Med Cell Longev. 2022; 20(22): 20. https://doi.org/10.1155/2022/2419412

Li Z, Wang L, Ren Y, Huang Y, Liu W, Lv Z, et al. Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases. Cell Death Discov. 2022; 8(1): 413. https://doi.org/10.1038/s41420-022-01200-4

Clemente GS, van Waarde A, Antunes IF, Dömling A, Elsinga PH. Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. Int J Mol Sci. 2020; 21(15): 5291. https://doi.org/10.3390/ijms21155291

Khaleel F, Oda NN, Abed BA. Disturbance of Arginase Activity and Nitric Oxide Levels in Iraqi Type 2 Diabetes Mellitus. Baghdad Sci J. 2018; 15(2): 189. https://doi.org/10.21123/bsj.2018.15.2.0189

Detroja TS, Samson AO. Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2. Molecules. 2022; 27(16): 5134. https://doi.org/10.3390/molecules27165134

Porembska Z, Kedra M. Early diagnosis of myocardial infarction by arginase activity determination. Clin Chim Acta. 1975; 60(3): 355–61. https://doi.org/10.1016/0009-8981(75)90078-9

Abdullah AH, Mohaisn IK, Nsaif AS, Safaryan AHM. Studying the impact of vitamin D deficiency in Iraqi acromegalic patients and its relation with some biochemical parameters. Ann Trop Med Public Heal. 2020; 23(11). https://doi.org/10.36295/ASRO.2020.231131

Sharma R, Kopchick JJ, Puri V, Sharma VM. Effect of growth hormone on insulin signaling. Mol Cell Endocrinol 2020 Dec; 518: 111038.https://doi.org/10.1016/j.mce.2020.111038

Aon YSA, Kadhim SJ, Al-Samarriae AY. Studying the genotype of Aryl Hydrocarbon Receptor-Interacting Protein (AIP) Gene (rs641081C>A) in ‎Iraqi Samples with Acromegaly Pituitary Adenoma. Baghdad Sci J. 2022 Dec 1; 19(6 SE-article): 1167. https://doi.org/10.21123/bsj.2022.6104

Hameed A. Assessment the Apelin, Glutathione S-transferase Polymorphism and some of Biochemical Parameters in Acromegaly Patients. PhD [dissertation]. Baghdad: College of Science for Women –University of Baghdad; 2019.

Farhan LO, Abed BA, J. KG, Salman IN. "Insulin Like Growth Factor Binding Protein 7 as a Novel Diagnostic Marker in Sera of Iraqi Patients with Acromegaly. Baghdad Sci J. 2023; 20(3): 979-985, https://doi.org/10.21123/bsj.2023.7797

Tabur S, Sezen H, Korkmaz H, Ozkaya M, Akarsu E. High Prolidase Levels may be a Marker of Irreversible Extracellular Matrix Changes in Controlled Acromegaly Patients?. Exp Clin Endocrinol Diabetes. 2016; 124(02): 82–6.https://doi.org/10.1055/s-0035-1564200

Moller N, Vendelbo MH, Kampmann U, Christensen B, Madsen M, Norrelund H, et al. Growth hormone and protein metabolism. Clin Nutr. 2009 Dec; 28(6): 597–603.https://doi.org/10.1016/j.clnu.2009.08.015

Hamwi GJ, Skillman TG, Tufts KC. Acromegaly. Am J Med. 1960 Oct; 29(4): 690–9. https://doi.org/10.1016/0002-9343(60)90101-7

Marques LR, Diniz TA, Antunes BM, Rossi FE, Caperuto EC, Lira FS, et al. Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol. Front Physiol. 2018; 9: 526 https://doi.org/10.3389/fphys.2018.00526

Takeda R, Tatami R, Ueda K, Sagara H, Nakabayashi H, Mabuchi H. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Eur J Endocrinol. 1982; 100(3): 358–62. https://doi.org/10.1530/acta.0.1000358

Beentjes JAM, van Tol A, Sluiter WJ, Dullaart RPF. Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atheroscler. 2000; 153(2): 491–8.https://doi.org/10.1016/s0021-9150(00)00433-0